Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

Bibliography

• ATMasi, GGHunder, JTLie, et al. The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33(8):1094-100
   PubMed Web of Science ®Google Scholar
• JCJennette, RJFalk, PABacon, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65(1):1-11
   PubMed Web of Science ®Google Scholar
• CComarmond, CPagnoux, MKhellaf, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65(1):270-81
   PubMed Web of Science ®Google Scholar
• RASinico, LDi Toma, UMaggiore, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum 2005;52(9):2926-35
   PubMed Web of Science ®Google Scholar
• RSablé-Fourtassou, PCohen, AMahr, et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 2005;143(9):632-8
   PubMed Web of Science ®Google Scholar
• FMoosig. Eosinophilic granulomatosis with polyangiitis: future therapies. Presse Méd 2013;42(4 Pt 2):510-12
   Google Scholar
• JGLanham, KBElkon, CDPusey, GRHughes. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore) 1984;63(2):65-81
   PubMed Web of Science ®Google Scholar
• LGuillevin, JAmouroux, BArbeille, RBoura. Churg–Strauss angiitis. Arguments favoring the responsibility of inhaled antigens. Chest 1991;100(5):1472-3
   Google Scholar
• PBottero, MBonini, FVecchio, et al. The common allergens in the Churg–Strauss syndrome. Allergy 2007;62(11):1288-94
   PubMed Web of Science ®Google Scholar
• SWieczorek, BHellmich, WLGross, JTEpplen. Associations of Churg–Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008;58(1):329-30
   Google Scholar
• AVaglio, DMartorana, UMaggiore, et al. HLA-DRB4 as a genetic risk factor for Churg–Strauss syndrome. Arthritis Rheum 2007;56(9):3159-66
   Google Scholar
• SWieczorek, BHellmich, LArning, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg–Strauss syndrome, but not with Wegener’s granulomatosis. Arthritis Rheum 2008;58(6):1839-48
   Google Scholar
• ATsukadaira, YOkubo, KKitano, et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg–Strauss syndrome. Allergy Asthma Proc 1999;20(1):39-44
   Google Scholar
• PCTai, MEHolt, PDenny, et al. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg–Strauss syndrome. Br Med J 1984;289(6442):400-2
   Google Scholar
• WHSchmitt, ECsernok, SKobayashi, et al. Churg–Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998;41(3):445-52
   Google Scholar
• EPeen, PHahn, GLauwers, et al. Churg–Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum 2000;43(8):1897-900
   Google Scholar
• VCottin, FTardy, DGindre, et al. Urinary eosinophil-derived neurotoxin in Churg–Strauss syndrome. J Allergy Clin Immunol 1995;96(2):261-4
   Google Scholar
• NHigashi, HMita, MTaniguchi, et al. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. J Allergy Clin Immunol 2004;114(6):1353-8
   PubMed Web of Science ®Google Scholar
• KPolzer, TKaronitsch, TNeumann, et al. Eotaxin-3 is involved in Churg–Strauss syndrome — a serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008;47(6):804-8
   Google Scholar
• MMuschen, UWarskulat, APerniok, et al. Involvement of soluble CD95 in Churg–Strauss syndrome. Am J Pathol 1999;155(3):915-25
   Google Scholar
• MKiene, ECsernok, AMuller, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg–Strauss syndrome. Arthritis Rheum 2001;44(2):469-73
   Google Scholar
• HTaki, KShinoda, HHounoki, et al. Serum interleukin-5 levels correlate with disease activity of Churg–Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid. Scand J Rheumatol 2010;39(4):341-3
   PubMed Web of Science ®Google Scholar
• CTermeer, JCSimon, ESchopf. Churg–Strauss syndrome associated with fluticasone therapy. Arch Dermatol 2001;137(11):1527-8
   Google Scholar
• BTerrier, IBieche, TMaisonobe, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg–Strauss syndrome. Blood 2010;116(22):4523-31
   Google Scholar
• BHellmich, ECsernok, WLGross. Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann N Y Acad Sci 2005;1051:121-31
   PubMed Web of Science ®Google Scholar
• NTsurikisawa, HSaito, COshikata, et al. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol 2013;33(5):965-76
   Google Scholar
• HSaito, NTsurikisawa, TTsuburai, KAkiyama. Involvement of regulatory T cells in the pathogenesis of Churg–Strauss syndrome. Int Arch Allergy Immunol 2008;146(Suppl 1):73-6
   Google Scholar
• NTsurikisawa, HSaito, COshikata, et al. An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis. BMC Immunol 2014;15:32
   PubMed Web of Science ®Google Scholar
• HSaito, NTsurikisawa, COshikata, et al. Increased interleukin-27 production by antigen-presenting cells promotes regulatory T cell differentiation and contributes to inducing a remission in patients with eosinophilic granulomatosis with polyangiitis. Int Arch Allergy Immunol 2013;161(Suppl 2):66-74
   Google Scholar
• HSaito, NTsurikisawa, TTsuburai, et al. Cytokine production profile of CD4+ T cells from patients with active Churg–Strauss syndrome tends toward Th17. Int Arch Allergy Immunol 2009;149(Suppl 1):61-5
   Google Scholar
• GGuida, AVallario, SStella, et al. Clonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndrome. Clin Immunol 2008;128(1):94-102
   PubMed Web of Science ®Google Scholar
• MBoita, GGuida, PCircosta, et al. The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). Clin Immunol 2014;152(1-2):152-63
   PubMed Web of Science ®Google Scholar
• MBoita, GRolla, RMallone, et al. Expression of NKG2D and CD107 in CD8(+) effector memory lymphocytes in Churg–Strauss syndrome. Clin Exp Rheumatol 2012;30(1 Suppl 70):S57-61
   Google Scholar
• BJManger, FEKrapf, MGramatzki, et al. IgE-containing circulating immune complexes in Churg–Strauss vasculitis. Scand J Immunol 1985;21(4):369-73
   Google Scholar
• AVaglio, JDStrehl, BManger, et al. IgG4 immune response in Churg–Strauss syndrome. Ann Rheum Dis 2012;71(3):390-3
   PubMed Web of Science ®Google Scholar
• JPunnonen, GAversa, BGCocks, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90(8):3730-4
   PubMed Web of Science ®Google Scholar
• RJFalk, RSTerrell, LACharles, JCJennette. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87(11):4115-19
   PubMed Web of Science ®Google Scholar
• HXiao, PHeeringa, PHu, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110(7):955-63
   PubMed Web of Science ®Google Scholar
• PHeeringa, EBrouwer, JWTervaert, et al. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998;53(2):253-63
   Google Scholar
• LGuillevin, CPagnoux, RSeror, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90(1):19-27
   PubMed Web of Science ®Google Scholar
• ABourgarit, PLe Toumelin, CPagnoux, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005;84(5):323-30
   PubMed Web of Science ®Google Scholar
• LGuillevin, PCohen, MGayraud, et al. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78(1):26-37
   PubMed Web of Science ®Google Scholar
• PCohen, CPagnoux, AMahr, et al. Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57(4):686-93
   PubMed Web of Science ®Google Scholar
• CRibi, PCohen, CPagnoux, et al. Treatment of Churg–Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58(2):586-94
   PubMed Web of Science ®Google Scholar
• MSamson, XPuéchal, HDevilliers, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013;43:60-9
   PubMed Web of Science ®Google Scholar
• MSamson, XPuéchal, HDevilliers, et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev 2014;13(9):945-53
   PubMed Web of Science ®Google Scholar
• FMoosig, WLGross, KHerrmann, et al. Targeting interleukin-5 in refractory and relapsing Churg–Strauss syndrome. Ann Intern Med 2011;155(5):341-3
   PubMed Web of Science ®Google Scholar
• Kde Groot, LHarper, DRJayne, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150(10):670-80
   PubMed Web of Science ®Google Scholar
• DJayne, NRasmussen, KAndrassy, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349(1):36-44
   PubMed Web of Science ®Google Scholar
• CPagnoux, AMahr, MAHamidou, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359(26):2790-803
   PubMed Web of Science ®Google Scholar
• TFHiemstra, MWalsh, AMahr, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304(21):2381-8
   PubMed Web of Science ®Google Scholar
• ETatsis, ASchnabel, WLGross. Interferon-alpha treatment of four patients with the Churg–Strauss syndrome. Ann Intern Med 1998;129(5):370-4
   PubMed Web of Science ®Google Scholar
• CMetzler, ECsernok, WLGross, BHellmich. Interferon-alpha for maintenance of remission in Churg–Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010;28(1 Suppl 57):24-30
   Google Scholar
• JHStone, PAMerkel, RSpiera, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363(3):221-32
   PubMed Web of Science ®Google Scholar
• RBJones, JWTervaert, THauser, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363(3):211-20
   PubMed Web of Science ®Google Scholar
• LGuillevin, CPagnoux, AKarras, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371(19):1771-80
   PubMed Web of Science ®Google Scholar
• RJPepper, MAFabre, CPavesio, et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47(7):1104-5
   PubMed Web of Science ®Google Scholar
• MKoukoulaki, KGSmith, DRJayne. Rituximab in Churg–Strauss syndrome. Ann Rheum Dis 2006;65(4):557-9
   PubMed Web of Science ®Google Scholar
• JSaech, KOwczarzyk, SRosgen, et al. Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010;69(6):1254-5
   PubMed Web of Science ®Google Scholar
• RCartin-Ceba, KAKeogh, USpecks, et al. Rituximab for the treatment of Churg–Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011;26(9):2865-71
   PubMed Web of Science ®Google Scholar
• JThiel, FHassler, USalzer, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). Arthritis Res Ther 2013;15(5):R133
   PubMed Web of Science ®Google Scholar
• AJMohammad, AHot, FArndt, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2014. [Epub ahead of print]
   Google Scholar
• KFChung, SEWenzel, JLBrozek, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343-73
   PubMed Web of Science ®Google Scholar
• WBusse, JCorren, BQLanier, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90
   PubMed Web of Science ®Google Scholar
• AGraziani, OQuercia, FGirelli, et al. Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis. A case report. Eur Ann Allergy Clin Immunol 2014;46(6):226-8
   PubMedGoogle Scholar
• DEWinchester, AJacob, TMurphy. Omalizumab for asthma. N Engl J Med 2006;355(12):1281-2
   Google Scholar
• MEWechsler, DAWong, MKMiller, LLawrence-Miyasaki. Churg–Strauss syndrome in patients treated with omalizumab. Chest 2009;136(2):507-18
   PubMed Web of Science ®Google Scholar
• HGOrtega, MCLiu, IDPavord, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198-207
   PubMed Web of Science ®Google Scholar
• EHBel, SEWenzel, PJThompson, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189-97
   PubMed Web of Science ®Google Scholar
• SKim, GMarigowda, EOren, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg–Strauss syndrome. J Allergy Clin Immunol 2010;125(6):1336-43
   PubMed Web of Science ®Google Scholar
• MSamson, XPuéchal, HDevilliers, et al. Eosinophilic granulomatosis with polyangitis (Churg–Strauss), polyarteritis nodosa and microscopic polyangitis with no initial Five Factor Score-defined poor prognosis factors (FFS = 0): baseline factors associated with cytotoxic agent and immunomodulator prescription. Presse Méd 2013;42:666
   Google Scholar
• BHellmich, OFlossmann, WLGross, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66(5):605-17
   PubMed Web of Science ®Google Scholar
• AKostianovsky, PCharles, JFAlves, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012;30(1 Suppl 70):S83-9
   Google Scholar
• FMoosig, JPBremer, BHellmich, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013;72(6):1011-17
   PubMed Web of Science ®Google Scholar
• LGuillevin, TGuittard, OBlétry, et al. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987;165(3):165-72
   Google Scholar
• MRMasjedi, SFTafti, ACheraghvandi, et al. Churg–Strauss syndrome following cessation of allergic desensitization vaccination: a case report. J Med Case Rep 2010;4:188
   Google Scholar
• EHChung, YJia, HOhnishi, et al. Leukotriene B4 receptor 1 is differentially expressed on peripheral T cells of steroid-sensitive and -resistant asthmatics. Ann Allergy Asthma Immunol 2014;112(3):211-16
   PubMed Web of Science ®Google Scholar
• MEWechsler, JMDrazen. Zafirlukast and Churg–Strauss syndrome. Chest 1999;116(1):266-7
   Google Scholar
• MEWechsler, DFinn, DGunawardena, et al. Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000;117(3):708-13
   PubMed Web of Science ®Google Scholar
• NNathani, MALittle, HKunst, et al. Churg–Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008;63(10):883-8
   Google Scholar
• THauser, AMahr, CMetzler, et al. The leucotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: a case–crossover study. Thorax 2008;63(8):677-82
   PubMed Web of Science ®Google Scholar
• KAKeogh, USpecks. Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003;115(4):284-90
   PubMed Web of Science ®Google Scholar
• JMarmursztejn, LGuillevin, RTrebossen, et al. Churg–Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) 2013;52(4):642-50
   PubMed Web of Science ®Google Scholar
• TNeumann, BManger, MSchmid, et al. Cardiac involvement in Churg–Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88(4):236-43
   PubMed Web of Science ®Google Scholar
• RMDennert, Pvan Paassen, SSchalla, et al. Cardiac involvement in Churg–Strauss syndrome. Arthritis Rheum 2010;62(2):627-34
   PubMed Web of Science ®Google Scholar
• LTCooper, KLBaughman, AMFeldman, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007;28(24):3076-93
   PubMed Web of Science ®Google Scholar
• HBaccouche, AYilmaz, DAlscher, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg–Strauss syndrome. Circulation 2008;117(13):1745-9
   PubMed Web of Science ®Google Scholar
• PYCourand, PCroisille, CKhouatra, et al. Churg–Strauss syndrome presenting with acute myocarditis and cardiogenic shock. Heart Lung Circ 2012;21(3):178-81
   Google Scholar
• CWYancy, MJessup, BBozkurt, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):1810-52
   PubMed Web of Science ®Google Scholar
• KSwedberg, MKomajda, MBohm, et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12(1):75-81
   Google Scholar
• MGroh, GMasciocco, EKirchner, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). J Heart Lung Transplant 2014;33(8):842-50
   PubMed Web of Science ®Google Scholar
• NOka, TKawasaki, MMatsui, et al. Two subtypes of Churg–Strauss syndrome with neuropathy: the roles of eosinophils and ANCA. Mod Rheumatol 2011;21(3):290-5
   PubMedGoogle Scholar
• JFCordier, VCottin, LGuillevin, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Presse Méd 2013;42(4 Pt 2):507-10
   Google Scholar
• LGuillevin, FLhote, MGayraud, et al. Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75(1):17-28
   PubMed Web of Science ®Google Scholar
• JKRichardson, DSandman, SVela. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 2001;82(2):205-9
   Google Scholar
• JRobson, HDoll, RSuppiah, et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74(1):177-84
   PubMed Web of Science ®Google Scholar
• MSamson, XPuéchal, HDevilliers, et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev 2014;13(2):197-205
   PubMed Web of Science ®Google Scholar
• PCGrayson, PAMonach, CPagnoux, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford) 2014. [Epub ahead of print]
   Google Scholar